Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.

No hay miniatura disponible

Fecha

2014-04-01

Director de tesis/Asesor

Título de la revista

ISSN de la revista

Título del volumen

Publicador

Lippincott, Williams & Wilkins

Editor

Compartir

Resumen

Purpose: The aim of this study was to describe the efficacy and safety of anti–interleukin 6 receptor antibody (tocilizumab [TCZ]) in patients with severe or refractory Takayasu arteritis (TA).

Methods: We describe 8 Colombian patients with severe and/or refractory TA treated with TCZ during a period of at least 9 months. Clinical, radiological, biological, and associated treatments were evaluated before, during, and after TCZ infusions.

Results: The median age at evaluation was 31 years (12–43 years). All patients were female and experienced clinical and biological improvement, in addition to a corticosteroid-sparing effect from a median dose of 50 mg/d at baseline (30–60 mg/d) to 6.25 mg/d (2.5–10 mg/d) at 9 months. In 4 cases, in which imaging studies were available, an improvement was observed.

Descripción

Palabras clave

Citación

ARK

ARXIV

Barcode

Bibcode

EAN13

DOI

http://dx.doi.org/10.1097/RHU.0000000000000098

EISSN

GOVDOC

Handle

IGSN

ISBN

ISMN

ISSN

1076-1608

ISTC

ISSN-L

LSID

Local

Other

http://journals.lww.com/jclinrheum/Abstract/2014/04000/Efficacy_and_Safety_of_Anti_Interleukin_6_Receptor.2.aspx

OLIB

PISSN

PMID

PURL

SICI

Slug

SoundCloud

UPC

URL

URN

YouTube

WOS